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ABSTRACT  
Exposure to aristolochic acid (AA) is associated with human nephropathy and urothelial 
cancer. Individual susceptibility to AA-induced disease likely reflects individual differences 
in enzymes that metabolize AA. Herein we evaluated AAI metabolism by human cytochrome 
P450 (CYP) 1A1 and 1A2 in two CYP1A-humanized mouse lines that carry functional human 
CYP1A1 and CYP1A2 genes in the absence of the mouse Cyp1a1/1a2 orthologs. Human and 
mouse hepatic microsomes, and human CYPs were also studied. Human CYP1A1 and 1A2 
were found to be principally responsible for reductive activation of AAI to form AAI-DNA 
adducts, and for oxidative detoxication to 8-hydroxyaristolochic acid AAIa), both in the 
intact mouse and in microsomes. Overall, AAI-DNA adduct levels were higher in CYP1A-
humanized mice relative to wild-type mice, indicating that expression of human CYP1A1 and 
1A2 in mice leads to higher AAI bioactivation than in mice containing the mouse CYP1A1 
and 1A2 orthologs. Furthermore, an exclusive role of human CYP1A1 and 1A2 in AAI 
oxidation to AAIa was observed in human liver microsomes under the aerobic (i.e. oxidative) 
conditions. Because CYP1A2 levels in human liver are at least 100-fold greater than those of 
CYP1A1, and there exists a >60-fold genetic variation in CYP1A2 levels in human 
populations, the role of CYP1A2 in AAI metabolism is clinically relevant. The results 
suggest that, in addition to CYP1A1 and 1A2 expression levels, in vivo oxygen concentration 
in specific tissues might affect the balance between AAI nitroreduction and demethylation, 
which in turn would influence tissue-specific toxicity or carcinogenicity. 
 
Key Words:  aristolochic acid nephropathy; Balkan endemic nephropathy, cytochrome P450; 
metabolism; aristolochic acid Ia, DNA adducts; CYP1A-humanized mouse models 
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The herbal drug aristolochic acid (AA) derived from Aristolochia species has been 
shown to be the cause of so-called Chinese herbs nephropathy (CHN), now termed 
aristolochic acid nephropathy (AAN) (Debelle et al., 2008; Schmeiser et al., 2009). The plant 
extract AA is a mixture of structurally related nitrophenanthrene carboxylic acids, the major 
components being aristolochic acid I (AAI; Fig. 1) and aristolochic acid II (AAII). AAN is a 
rapidly progressive renal fibrosis that was observed initially in a group of Belgian women 
who had ingested weight loss pills containing Aristolochia fangchi (Vanherweghem et al., 
1993; Nortier et al., 2000). Within a few years of taking the pills, AAN patients also showed 
a high risk of upper urothelial tract carcinoma (about 50%) and, subsequently, bladder 
urothelial carcinoma (Lemy  et al., 2008). In the meantime, similar cases have been reported 
elsewhere in Europe and Asia (Schmeiser et al., 2009). More recently, exposure to AA has 
been linked to Balkan endemic nephropathy (BEN) and its associated urothelial cancer (Arlt 
et al., 2007; Grollman et al., 2007). This nephropathy is endemic in certain rural areas of 
Serbia, Bosnia, Croatia, Bulgaria and Romania.  
Exposure to AA was demonstrated by the identification of specific AA-DNA adducts in 
urothelial tissue of AAN and BEN patients (Arlt et al.,  2002; Grollman et al., 2007; 
Schmeiser et al., 1996). The most abundant DNA adduct detected in patients is 7-
(deoxyadenosin-N6-yl)-aristolactam I (dA-AAI), which leads to characteristic AT→TA 
transversions. Such AT→TA mutations have been observed in the TP53 tumor suppressor 
gene in tumors from AAN and BEN patients (Arlt et al., 2007; Grollman et al., 2007), 
indicating a probable molecular mechanism associated with AA-induced carcinogenesis (Arlt 
et al., 2011b). AA was recently classified as carcinogenic to humans (Group 1) by the IARC 
(Grosse et al., 2009). 
The activation pathway for AA is nitroreduction catalyzed by both cytosolic and 
microsomal enzymes; in this process NAD(P)H:quinone oxidoreductase (NQO1) is the most 
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efficient cytosolic enzyme (Stiborova et al., 2003; 2008) (Fig. 1). In human hepatic 
microsomes AAI is activated by cytochrome P450 (CYP) 1A2 and to a lesser extent by 
CYP1A1; P450 oxidoreductase (POR) also plays a minor role (Stiborova et al., 2001). 
Whereas the enzymes catalyzing the reductive activation of AAI leading to covalent DNA 
adducts have been widely investigated, those participating in its detoxication have not been 
extensively studied so far. Several studies have indicated that induction of CYP1A protects 
mice from AAI-induced acute renal injury (Xue et al., 2008). One detoxication metabolite 
identified is 8-hydroxyaristolochic acid I (aristolochic acid Ia, AAIa; Fig. 1), which is formed 
by AAI demethylation, and which leads, in turn, to glucuronide or sulfate esters (Chan et al., 
2006; Shibutani et al., 2010). Human and rodent CYP1A1 and 1A2 can oxidize AAI to AAIa 
in vitro (Levova et al., 2011; Rosenquist  et al., 2010; Sistkova  et al., 2008) and CYP1A1 
and 1A2 in mice appear to mediate this reaction in vivo (Arlt et al., 2011a; Rosenquist  et al., 
2010). CYP1A1 and 1A2 also reductively activate AAI in human and rodent livers (Levova 
et al., 2011; Stiborova et al., 2001; 2005a; 2005c; 2008). However, knowledge of the balance 
between oxidative detoxication and reductive activation of AAI by these human enzymes in 
vitro and in vivo is still lacking. 
Much information about CYP regulation and function has been obtained by in-vitro 
studies, but, before extrapolation from in-vitro data to in-vivo pharmacokinetics can be made, 
additional factors need to be considered such as route-of-administration, absorption, renal 
clearance, and tissue-specific CYP expression (Nebert, 2006). Moreover, human/rodent 
CYP1A1 and 1A2 orthologs are known to exhibit species-specific differences in substrate 
preference and rates of metabolism (Aoyama et al., 1989; Turesky, 2005).   
In the present study we evaluated the oxidative detoxication and the reductive activation 
of AAI mediated by human CYP1A1 and 1A2 expressed in transgenic mouse models. We 
employed two humanized mouse lines, both carrying functional human CYP1A1 and CYP1A2 
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genes in place of the orthologous mouse genes; one line carries the high-affinity aryl 
hydrocarbon receptor (AHR) [hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1] (Dragin  et al., 2007), 
whereas the other line carries the poor-affinity AHR 
[hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd] (Shi  et al., 2008). The latter line is believed to be 
more relevant to human risk assessment vis-à-vis human CYP1A1 and CYP1A2 substrates, 
because poor-affinity, rather than high-affinity, AHR is known to exist in human populations. 
DNA adduct formation in vivo and in vitro was investigated by the 32P-postlabeling method. 
Urinary AAIa and the CYP-mediated formation of AAIa in vitro in hepatic microsomes and 
by human recombinant CYPs were measured by HPLC.  
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MATERIALS AND METHODS 
Chemicals 
The natural mixture of AA consisting of 38% AAI and 58% AAII was purchased from Sigma 
Chemical Co (St Louis, MO, USA). AAI (as sodium salt) was isolated from the mixture by 
preparative HPLC; its purity was 98% as estimated by HPLC (Schmeiser et al., 1996). 
 
Animal treatment  
The hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1 and hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd 
lines, both on a >99.8% C57BL/6J background, were generated as reported (Dragin  et al., 
2007; Shi  et al., 2008). Age-matched C57BL/6J mice wild-type (WT) mice were purchased 
from The Jackson Laboratory (Bar Harbor, ME, USA). All animal experiments were 
approved by, and conducted in accordance with, the National Institute of Health standards for 
the care and use of experimental animals and the University of Cincinnati Medical Center 
Institutional Animal Care and Use Committee. Groups of female mice (3 months old; 25-30 
g; n = 4/group) were treated with a single dose of 50 mg/kg body weight AAI by oral gavage. 
AAI was dissolved in water at a concentration of 5 mg/mL. Control mice received gavage of 
solvent (water) only. Animals were killed 24 h after treatment. Several organs (liver, lung, 
kidney, bladder, spleen and colon) were removed, snap frozen, and stored at −80°C until 
analysis. It is noteworthy that treatment of CYP1A-humanized mice with AAI was carried out 
in parallel with Cyp1a1(−/−),  Cyp1a2(−/−) and Cyp1a1/1a2(−/−) mouse line treatments (Arlt 
et al., 2011a), whereas the WT mouse line was used as reference in both studies to allow 
direct comparison of the results.  
 
DNA adduct analysis by 32P-postlabeling  
 7
DNA from tissues was isolated by standard phenol/chloroform extraction. 32P-postlabeling 
analysis (Phillips and Arlt, 2007) using the nuclease P1 enrichment version, and thin-layer 
chromatography (TLC) and HPLC was performed as described (Schmeiser et al., 1996). 
Chromatographic conditions for TLC on polyethylenimine-cellulose plates (10 cm × 20 cm; 
Macherey-Nagel, Düren, Germany) were: D1, 1.0 M sodium phosphate, pH 6.8; D3: 3.5 
lithium-formate, 8.5 M urea, pH 4; D4, 0.8 M lithium chloride, 0.5 M Tris-HCl, 8.5 M urea, 
pH 9; D5, 1,7 M sodium phosphate, pH 6. After chromatography, TLC sheets were scanned 
using a Packard Instant Imager (Dowers Grove, USA) and DNA adduct levels (RAL, relative 
adduct labeling) were calculated as described (Schmeiser et al., 1996). Results were 
expressed as DNA adducts/108 nucleotides. AA-DNA adducts were identified using reference 
compounds as described (Schmeiser et al., 1996). Urothelial DNA samples from AAN 
patients were included in the analysis for comparison (Nortier et al., 2000).  
 
Determination of AAIa by HPLC in mouse urine 
Urine samples (0.4-1.7 mL) collected from all mice treated with AAI were mixed with 4 vol. 
of methanol, centrifuged (1000 RPM) for 4 min, and the supernatants then evaporated to 
dryness. The residues were dissolved in 100 µL of methanol and analyzed by HPLC. HPLC 
was performed with a reverse-phase column (Nucleosil 100-5 C18, 25 × 4.0 mm, 5 µm; 
Macherey-Nagel) proceeded by a C-18 guard column, using a linear gradient of 20-60% 
acetonitrile in 100 mM triethylammonium acetate in 55 min with a flow rate of 0.6 mL/min. 
HPLC was carried out with a Dionex HPLC pump P580 with UV/VIS UVD 170S/340S 
spectrophotometer detector set at 254 nm, and peaks were integrated with 
CHROMELEON™ 6.01 integrator. A peak eluting at retention time (r.t.) 23.1 min was 
identified as AAIa using mass-spectroscopy analysis [compare Fig. 3A in Arlt et al., 
(2011a)].  Mass spectra were measured on MALDI-TOF/TOF ultraFLEX III mass 
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spectrometers (Bruker-Daltonics, Bremen, Germany). Positive spectra were calibrated 
externally using the monoisotopic [M+H]+ ions of PepMixII calibrant (Bruker-Daltonics, 
Bremen) or matrix peaks. A 10 mg/mL solution of α-cyano-4-hydroxy-cinnamic acid, or 50 
mg/mL solution of 2,5-dihydrobenzoic acid in 50% MeCN/0.1% TFA, was used as a MALDI 
matrix. A 0.5-µL sample dissolved in MeCN was directly mixed with 0.5 µL of matrix 
solution and allowed to dry at ambient temperature on the target. The MALDI-TOF positive 
spectra were collected in reflector mode (Arlt et al., 2011a; Levova et al., 2011).  
 
Determination of creatinine in urine samples 
Creatinine concentrations in urine samples were determined spectrophotometically using a 
HELIOS Alpha spectrophotometer (Thermo Spectronics, UK) by the procedure described in 
the Creatinine Kit (BioSystems, Spain). 
  
Preparation of microsomes and cytosols  
Hepatic, renal and pulmonary microsomes, and hepatic and renal cytosols from CYP1A-
humanized and WT mice were isolated as described (Stiborova et al., 2001; 2005a). Because 
treating mice with AAI might influence levels and activities of biotransformation enzymes, 
microsomes and cytosols were isolated both from organs of control (untreated) mice and 
from those of mice treated with a single dose of 50 mg/kg body weight AAI by oral gavage 
(see above) and used for further analysis. Pooled microsomal and cytosolic fractions (n = 4 
mice/group) were used for further analysis. Each mouse microsomal sample was analyzed for 
specific CYP1A1 and 1A2 activities by monitoring the following reactions: ethoxyresorufin 
O-deethylation (EROD) (CYP1A1/2) and methoxyresorufin O-deethylation (MROD) 
(CYP1A2). CYP1A1 activity was also determined using Sudan I oxidation to its C-
hydroxylated metabolites (4’-hydroxy- and 6-hydroxy-Sudan I) in the presence of 
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ketoconazole, a CYP3A4 inhibitor (Stiborova et al., 2002; 2005b). POR activity in hepatic 
microsomes was measured using cytochrome c as substrate (Stiborova et al., 2001).  
Male human (pooled sample; cat. no. 452172) and female human hepatic microsomes 
(pooled sample; cat. no. 452183) were purchased from Gentest Corp. (Woburn, MI, USA). 
Human hepatic microsomes from individual donors (HG93, HG03, HG74, HG06, HK27, 
HG42, HG112, HG56, HG43, HG89, HG32, HK31, HK23, and HK34; Gentest) were also 
included. Donors ranged in age from 2 to 71 years and included seven men and seven 
women; drug and/or alcohol abuse history of the samples is described in Gentest protocols. 
Each human microsomal sample has been characterized for CYP and protein contents and 
specific CYP activities by Gentest Corp. We re-analyzed each microsomal preparation for 
specific CYP and POR activities by assays described in the protocols of Gentest Corp. Our 
data were similar to those reported by Gentest Corp. in their specification sheets. Moreover, 
we characterized these samples for the CYP1A1 marker activity using Sudan I, as described 
above. Data are shown in Table 1. Protein concentrations in microsomal and cytosolic 
fractions were assessed using the bicinchoninic acid protein assay with bovine serum albumin 
as a standard. 
 
Microsomal incubations to study AAI demethylation 
Incubation mixtures, in a final volume of 250 µL, consisted of 100 mM potassium phosphate 
buffer (pH 7.4), 1 mM NADPH, 1 mg human or mouse hepatic or mouse renal and 
pulmonary microsomal protein and 10 µM AAI. Incubations with microsomes were carried 
out at 37°C for 20 min; AAI oxidation (demethylation) to AAIa was determined to be linear 
up to 25 min. Control incubations were carried out (i) without microsomes, (ii) without 
NADPH or (iii) without AAI. Supersomes isolated from insect cells transfected with 
baculovirus constructs containing cDNA of single human CYPs (CYP1A1, 1A2, 1B1, 2A6, 
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2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4 and 3A5), and expressing POR and/or cytochrome b5 
were obtained from Gentest and tested for their efficiencies to oxidize AAI. Incubation 
mixtures, in a final volume of 250 µL, consisted of 100 mM potassium phosphate buffer (pH 
7.4), 1 mM NADP+, 10 mM MgCl2, 10 mM D-glucose 6-phosphate, 1 U/mL D-glucose 6-
phosphate dehydrogenase (NADPH-generating system), 50 nM CYPs in Supersomes  and 
10 µM AAI. For controls, Supersomes containing POR alone were used. AAI and its 
metabolites (i.e. AAIa) were extracted from incubation mixtures twice with ethyl acetate (2 × 
1 mL) and evaporated to dryness; residues were dissolved in 30 µL of methanol and 
subjected to reverse-phase HPLC as described above.  
 
Microsomal AAI-DNA adduct formation 
Deaerated and argon-purged incubation mixtures, in a final volume of 750 µL, consisted of 
50 mM potassium phosphate buffer (pH 7.4), 1 mM NADPH, 1 mg of hepatic or renal 
microsomal protein, 0.5 mg of calf thymus DNA (2 mM dNp) and 0.5 mM AAI. The reaction 
was initiated by adding NADPH. Microsomal incubations were carried out at 37°C for 60 
min; microsomal-mediated AAI-derived DNA adduct formation was found to be linear up to 
2 hr (Stiborova et al., 2005a). Control incubations were carried out (i) without microsomes, 
(ii) without NADPH, (iii) without DNA or (iv) without AAI. After extraction with ethyl 
acetate, DNA was isolated from the residual water phase by the phenol/chloroform extraction 
method as described (Arlt et al., 2011a; Stiborova et al., 2005a). 
 
Cytosolic AAI-DNA adduct formation 
The deaerated and argon-purged incubation mixtures, in a final volume of 750 µL, consisted 
of 50 mM Tris-HCl buffer (pH 7.4), containing 0.2% Tween 20, 1 mM NADPH, 1 mg mouse 
hepatic or renal cytosolic protein, 0.5 mg calf thymus DNA (2 mM dNp) and 0.5 mM AAI as 
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described previously (Stiborova et al., 2003). Incubations with human cytosolic fractions 
were carried out at 37°C for 60 min; AAI-derived DNA adduct formation was found to be 
linear up to 2 hr (Stiborova et al., 2003). Control incubations were carried out (i) without 
cytosol, (ii) without NADPH, (iii) without DNA or (iv) without AAI. DNA was then isolated 
as described above.  
 
Inhibition studies  
The following chemicals were used to inhibit AAI demethylation by human hepatic 
microsomes and human recombinant CYP enzymes to AAIa: α-naphthoflavone (α-NF), 
which inhibits CYP1A1 and 1A2 (Stiborova et al., 2001; 2005a); furafylline, which inhibits 
CYP1A2 (Stiborova et al., 2001); diamantane, which inhibits CYP2B6 (Stiborova et al., 
2002); sulfaphenazole, which inhibits CYP2C; quinidine, which inhibits CYP2D6; 
diethyldithiocarbamate (DDTC), which inhibits CYP2E1 and CYP2A6; and ketoconazole 
(KC), which inhibits CYP3A4 (Rendic and Di Carlo, 1997). Inhibitors were dissolved in 2.5 
µL methanol (except for DDTC that was dissolved in distilled water) to yield final 
concentrations of 0.001-1 mM in the incubation mixtures containing microsomes or human 
recombinant CYPs. These were incubated at 37°C for 10 min with the NADPH-generating 
system prior to adding AAI, and then incubated for an additional 20 min at 37°C. AAI and its 
metabolite AAIa were extracted from incubation mixtures twice with ethyl acetate (2 × 1 mL) 
and analyzed by HPLC as described above. 
In experiments investigating the inhibition of reductive AAI bioactivation (i.e. DNA 
adduct formation) in mouse hepatic microsomes, the following chemicals were used: α-NF; 
ellipticine (E), which competes with CYP1A1 substrates, thus inhibiting efficiently CYP1A1-
mediated oxidation of other substrates (Stiborova et al., 2004); furafylline; and α-lipoic acid 
(α-LA), which inhibits POR (Stiborova et al., 2005a). Inhibitors were dissolved in 7.5 µL of 
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methanol, to yield a final concentration of 0.1 mM in the incubation mixtures. Mixtures were 
incubated at 37°C for 10 min with NADPH prior to adding AAI, and then incubated further 
for 1 hr at 37°C. After the incubation, DNA was isolated as described above. 
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RESULTS 
AAI-DNA adduct formation in WT versus CYP1A-humanized mice 
AAI-DNA adduct formation was determined by 32P-postlabeling in the liver, lung, 
kidney, bladder, spleen and colon of WT, hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1 and 
hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd mice treated with a single oral dose of 50 mg/kg 
body weight AAI for 24 h. Adduct patterns induced by AAI in all organs tested were 
qualitatively similar to those found in vivo in humans, consisting of two major adducts (spot 1 
and 2) and one minor adduct (spot 3) (see Fig. 2, insert) (Nortier et al., 2000; Schmeiser et al., 
1996). These adducts have previously been identified (Schmeiser et al., 1996) as 7-
(deoxyadenosin-N6-yl)aristolactam I (spot 1; dA-AAI), 7-(deoxyguanosin-N2-yl)aristolactam 
I (spot 2; dG-AAI) and 7-(deoxyadenosin-N6-yl)aristolactam II (spot 3; dA-AAII). No 
adducts were observed in DNA of untreated animals.  
In all mouse lines, the adduct levels were much higher in kidney than in other organs 
(Fig. 2). Compared with WT mice, up to 2.5-fold higher levels of AAI-DNA adducts were 
found in liver, lung, kidney, urinary bladder, spleen and colon of  
hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1 and in liver and kidney of 
hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd mice (P<0.01). These findings indicate that 
expression of human CYP1A1 and 1A2 in mice lacking the mouse orthologous enzymes, 
increases the activation of AAI to reactive intermediates capable of forming DNA adducts in 
several organs.  
 
Determination of AAIa in mouse urine 
CYP1A-humanized mice also exhibited AAI oxidation, as measured by HPLC analysis of 
urine [compare peak with r.t. 23.1 min in Fig. 3A in Arlt et al. (2011a)], representing AAI 
detoxication. Using positive MALDI-TOF-TOF peaks at m/z 327.029 and 328.043 were 
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recorded, representing the molecular ions [M-H]+ and [M]+ of AAIa, respectively, and peaks 
at m/z 283.021 and 311.031, representing ions of AAIa fragments; these data confirmed that 
the metabolite is AAIa (Arlt et al., 2011a; Levova et al., 2011). AAI was not detected in urine 
from any mouse line. Compared with WT mice, 1.2- and 1.6-fold higher concentrations of 
AAIa were found in urine of hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1 and 
hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd mice, respectively (Fig. 3). Because the high-affinity-
AHR mouse would be more easily induced, in turn it would also be more likely to exhibit 
enhanced clearance (detoxication, degradation) of any inducer (e.g. AAI) that can be 
metabolized by CYP1A, 
 
Microsomal versus cytosolic activation of AAI 
CYP-mediated AAI-DNA adduct formation was also investigated in hepatic microsomes 
isolated from WT and CYP1A-humanized mice either untreated (i.e. control) or pretreated 
with 50 mg/kg body weight AAI by oral gavage (see Materials and methods). These 
incubations were performed under hypoxic conditions in which each incubation mixture was 
purged with a stream of argon for 3 min before the addition of AAI. Although most of the 
oxygen was removed, we cannot exclude the negligible presence of O2 in the microsomal 
membranes and lumen.  
AAI was reductively activated by hepatic microsomes from all mouse lines, as evidenced 
by AAI-DNA adduct formation (Fig. 4), generating the same pattern of DNA adducts as that 
obtained in vivo in mice (compare Fig. 2, insert). No adducts were observed in control 
incubations carried out in parallel without microsomes, or without DNA, or without AAI. 
Higher levels (1.5- to 2.4-fold) of AAI-DNA adducts were detected in incubations with 
hepatic microsomes from untreated CYP1A-humanized mice relative to microsomal 
incubations from WT mice (Fig. 4A). The increase in total AAI-DNA adduct levels 
 15
correlated with an increase in Sudan I oxidation (marker for human CYP1A1) in hepatic 
microsomes of both CYP1A-humanized mice and with EROD (marker for CYP1A1/2) or 
MROD (marker for CYP1A2) activity in hepatic microsomes of 
hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd mice (Fig. 5B-D). With hepatic microsomes of WT 
mice pretreated with AAI, more than 3-fold higher levels of AAI-DNA adducts were found 
relative to those of untreated WT mice (P<0.01) (Fig. 4A and 4B). Again, these higher levels 
of AAI-DNA adducts corresponded to increased activities of CYP1A1 and 1A2 (Sudan I 
oxidation, EROD and MROD) in these microsomes (compare Fig. 5). Collectively, these 
results clearly show that human CYP1A1 and 1A2 activate AAI to intermediates capable of 
forming DNA adducts and that hepatic microsomes containing the human enzymes are more 
effective in AAI bioactivation, compared with mouse microsomal CYP1A1 and 1A2.  
However, the increase in AAI-DNA adduct formation found in in-vitro incubations with 
hepatic microsomes isolated from CYP1A-humanized mice treated with AAI (Fig. 4B) did 
not correspond to CYP1A activities in these microsomes (compare Fig. 5F-5H). Lower 
activities of CYP1A1 and 1A2 were found in these microsomes with their marker substrates 
relative to those of WT mice (compare Fig. 5F-5H). Results of experiments using inhibitors 
of CYP1A1, CYP1A2 and POR might explain these discrepancies (Fig. 6). With all samples 
of hepatic microsomes isolated from mice pretreated with AAI, AAI-DNA adduct formation 
was found to be inhibited by α-NF, most effectively in WT microsomes (down to 40%), 
followed by microsomes from both CYP1A-humanized mice (down to 55%). Ellipticine 
decreased AAI-DNA adduct formation to ~75% in all hepatic microsomes. Furafylline 
decreased DNA adduct levels by AAI to ~50-80% in all hepatic microsomal samples. 
Interestingly, even though POR activities in all hepatic microsomes did not differ 
significantly (Supporting Table 1), the POR inhibitor α-LA prevented AAI-DNA adduct 
formation, but only in hepatic microsomes isolated from CYP1A-humanized mice. α-LA was 
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most effective as an inhibitor in the hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1 line, whereas no 
effect was observed in microsomes isolated from WT mice (Fig. 6).  
Our experiments with CYP1A inhibitors support the above finding that most AAI 
activation in hepatic microsomes from WT mice pretreated with AAI is attributed to 
CYP1A1 and 1A2. In contrast, the inhibitory results with α-LA in hepatic microsomes from 
CYP1A-humanized mice pretreated with AAI (principally seen in 
hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1 mice) suggest that POR, in addition to CYP1A1 and 
1A2, might also contribute to AAI-DNA adduct formation (Fig. 6B and 6C). 
Renal and pulmonary microsomes isolated from mice pretreated with AAI were much 
less effective in activating AAI than hepatic microsomes (compare Fig. 4C and 4D). 
Pulmonary microsomes from CYP1A-humanized mice were slightly less effective in 
activating AAI than microsomes from WT mice (Fig. 4D). 
Because NQO1 is an important enzyme catalyzing the reductive activation of AAI, we 
compared renal and hepatic cytosols of WT and CYP-humanized mice isolated from AAI-
treated mice. No differences were observed in cytosols from either organ in the three mouse 
lines. As expected, hepatic cytosols were more active than renal cytosols (Supporting Fig. 1A 
and 1B). 
 
Human and mouse hepatic microsomes oxidize AAI to AAIa 
To examine the role of human CYP1A1 and 1A2 in oxidative detoxication of AAI, we 
performed in-vitro incubations using the same hepatic mouse microsomes as those used in the 
experiments above, except that incubations were carried out under aerobic conditions. In 
addition, human hepatic microsomes, both pooled microsomes as well as microsomes from 
fourteen individual human donors, were employed in this study.  
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All mouse and human hepatic microsomes were able to metabolize AAI to AAIa. A 1.1- 
to 1.5-fold increase in AAIa formation was found in hepatic microsomes from untreated 
CYP1A-humanized mice, compared with that in WT mice (Fig. 5A). This increase correlated 
with enhanced Sudan I oxidation (marker for CYP1A1; Fig. 5D) in hepatic microsomes of 
both CYP1A-humanized mouse lines and with EROD (marker for CYP1A1/2; Fig. 5B) and 
with MROD (marker for CYP1A2; Fig. 5C) activity in hepatic microsomes of 
hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd mice. Collectively, these data show that CYP1A1 and 
1A2 are responsible for AAI demethylation to form AAIa, and that microsomes containing 
human CYP1A1 and 1A2 seem to be more effective than microsomes containing the mouse 
orthologous enzymes.  
The amounts of AAIa formed in hepatic microsomes of mice pretreated with AAI were 
greater than those of untreated mice. In microsomes isolated from WT mice pretreated with 
AAI, 1.4-fold greater amounts of AAIa were formed than from untreated WT mice (P<0.01) 
(compare Fig. 5A and 5E). In contrast, AAI pretreatment of mice led to ~70% decrease in 
AAIa formation catalyzed by hepatic microsomes from CYP1A-humanized mice. Again, the 
decrease in AAI demethylation to AAIa correlated with marker activities of CYP1A enzymes 
(compare Fig. 5E-5H). These results indicate that AAI induces CYP1A activities in WT 
mice, whereas AAI does not induce human CYP1A in the humanized mouse lines.                                                                                           
In contrast to mouse hepatic microsomes, mouse renal and pulmonary microsomes did 
not oxidize AAI to AAIa under the same experimental conditions (data not shown). 
To further resolve the importance of human CYP1A1- and 1A2-mediated demethylation 
of AAI to AAIa, three more experimental approaches were employed: (i) use of 
SupersomesTM, (ii) correlation of CYP enzyme activities in human hepatic microsomes with 
AAIa formation by the same microsomes, and (iii) selective enzyme inhibition in human 
microsomes. 
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Oxidation of AAI to AAIa in SupersomesTM  
Experiments were conducted using SupersomesTM containing human CYPs, POR and/or 
cytochrome b5 (Fig. 7). Recombinant human CYPs used in these experiments efficiently 
oxidized their typical substrates (data not shown). Human CYP1A1 was the most efficient at 
demethylating AAI to AAIa, followed by CYP1A2. Other human CYPs, including CYP1B1, 
2C, 2D6 and 3A, were also capable of AAI demethylation, but to a much lesser extent. 
Cytochrome b5 had essentially no influence on product yield (Fig. 7). No AAIa formation 
occurred in control incubations with SupersomesTM containing POR alone. 
 
Correlation of CYP enzyme activities in human hepatic microsomes with AAI demethylation 
to AAIa 
All human hepatic microsomes used in the present study were able to catalyze reactions 
known to be associated with specific CYP enzymes (Table 1). Large inter-individual 
variations in the catalytic activities were evident among different hepatic microsomal samples 
(Table 1). As shown in Table 1, AAIa formation in human hepatic microsomes also displayed 
wide inter-individual variation. The levels of AAIa formed in these microsomes were highly 
significantly correlated with Sudan I oxidation, a marker for CYP1A1, and with phenacetin 
O-deethylase activity, a marker for CYP1A2 (Table 2). Likewise, using bilinear regression 
between activities of CYP1A1 (Sudan I oxidation) plus CYP1A2 (phenacetin-O-
deethylation) and AAIa formation, a highly significant correlation was found (R=0.899). No 
significant correlation was seen with any of the other nine CYPs examined, or with total 
levels of CYP content, vis-a-vis AAIa formation. These findings indicate that human 
CYP1A1 and 1A2 are the major hepatic enzymes catalyzing AAI demethylation. 
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Effect of inhibitors of CYP enzymes on AAI demethylation catalyzed by human hepatic 
microsomes and human CYPs 
Inhibition experiments supported the role of CYP1A1 and 1A2 in AAI demethylation in 
human hepatic microsomes. As shown in Table 3, α-NF and furafylline were effective in 
inhibiting AAIa formation. Moreover, most inhibitors of other CYP enzymes (diamantane, 
sulfaphenazole, quinidine and DDTC) were ineffective.  
However, although human liver is enriched for many CYPs, some of these enzymes are 
expressed in liver at very low levels (e.g. CYP1A1, 1B1, and 2B6); this feature can therefore 
influence the degree of their inhibition. In addition, it should be noted that results with 
inhibitors are sometimes difficult to interpret because one inhibitor may be more effective 
with one substrate than another. Therefore, we also studied the effects of these specific CYP 
inhibitors on AAIa formation by the recombinant human CYPs.  
As shown in Table 3, α-NF and furafylline strongly inhibited AAI oxidation to AAIa 
catalyzed by human recombinant CYP1A1 and 1A2. Therefore, inhibition of AAI 
demethylation by these compounds in human microsomes must reflect inhibition of these 
enzymes. Because of the low efficiency of human recombinant CYP3A4 to catalyze AAIa 
formation (compare Fig. 7), CYP3A4 inhibition by ketoconazole could not be determined in 
Supersomes™. However, we did find that ketoconazole inhibits oxidation of AAI to AAIa 
catalyzed by human recombinant CYP1A1 and 1A2 (Table 3). Therefore, the effect of 
ketoconazole on AAI demethylation in human hepatic microsomes is probably not due to 
inhibition of CYP3A4, but rather to inhibition of CYP1A1 and 1A2.  
 
Contribution of individual human liver microsomal CYP enzymes to AAI demethylation 
Based on our data showing AAI oxidation to AAIa by individual human recombinant CYPs 
(see Fig. 7), and inhibition of individual CYPs in human hepatic microsomes (see Table 3), as 
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well as the typical expression levels of CYP enzymes in human hepatic microsomes (Rendic 
Di Carlo, 1997), we were able to estimate the contribution of individual CYPs to the 
formation of AAIa in human hepatic microsomes. Even though human CYP1A1 is the most 
effective enzyme in AAI demethylation (Fig. 7), its contribution to AAIa formation in human 
hepatic microsomes is lower than that of CYP1A2 due to its extremely low expression in 
human livers (i.e. <1% of total hepatic CYP) (Ikeya et al., 1989; Stiborova et al., 2002; 
2005a).  CYP1A1 contributes ~13% to AAIa formation in human liver, whereas CYP1A2 
contributes ~87%. No other human hepatic CYP appears to participate significantly in AAI 
demethylation to AAIa in human liver microsomes. These findings correspond well with 
results showing high correlation coefficients that were seen only between activities of 
CYP1A1 and 1A2 and AAIa formation (compare Table 2).  
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DISCUSSION 
A large body of evidence indicates that the nephrotoxic and carcinogenic effects of AAI are 
reflected largely by metabolism. Whereas AAI reduction leads to bioactivation to a cyclic 
acylnitrenium ion that generates DNA adducts, oxidation of AAI to AAIa is a detoxication 
reaction because AAIa is much less toxic than AAI (Shibutani et al., 2010). In addition, AAIa 
and its conjugates, the glucuronide, the acetate and the sulfate esters, are readily excreted in 
urine (Chan et al., 2006).  
AAIa formation was recently found to be catalyzed mainly by human and rat CYP1A1 
and 1A2 in vitro (Levova et al., 2011; Rosenquist  et al., 2010; Sistkova  et al., 2008) and by 
mouse CYP1A1 and 1A2 in vivo (Arlt et al., 2011a; Rosenquist  et al., 2010). However, 
depending on experimental conditions (i.e. oxygen concentrations), human CYP1A1 and 1A2 
also reductively activate AAI to form DNA adducts in vitro (Levova et al., 2011; Stiborova et 
al., 2001; 2005a; 2005c). In the present report we therefore investigated the balance between 
oxidative detoxication and reductive activation of AAI in vitro and in vivo in detail.  
Herein we employed the CYP1A-humanized hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1 and 
hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd mouse lines that carry functional human CYP1A1 and 
CYP1A2 genes and lack the mouse orthologous genes; the former line harbours the high-
affinity AHR, the latter has the poor-affinity AHR (Dragin  et al., 2007; Shi  et al., 2008). We 
have demonstrated for the first time that human CYP1A1 and 1A2 enzymes are responsible 
for both AAI activation (to a cyclic nitrenium ion that forms DNA adducts) and AAI 
demethylation to AAIa (a detoxication pathway), both in vitro and in the intact animal. Both 
reductive activation and oxidative detoxification of AAI in the humanized lines are more 
extensive than in the WT mouse line, without a clear difference between the contribution of 
CYP1A1 and 1A2. Also, we have proven the participation of mouse CYP1A1 and 1A2 in 
reductive activation by using selective inhibitors of these enzymes in in-vitro experiments.   
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Our results are consistent with a recent study employing the HRN (Hepatic Cytochrome 
P450 Reductase Null) mouse model in which POR-mediated CYP activity is deleted 
specifically in liver (Levova et al., 2011). Moreover, the essential role of mouse CYP1A1 and 
1A2 in AAI metabolism in vivo has also been confirmed in a study using Cyp1a-knock-out 
mouse models from which the lines used in the present study were created (Arlt et al., 
2011a).  
These results indicate that AAI is a ligand substrate for the CYP1A1 and 1A2 enzymes at 
low oxygen concentrations, and is reduced instead of oxidized during the CYP-mediated 
reaction cycle. In contrast, under aerobic conditions AAI is a classical substrate of CYP1A1 
and 1A2 in which one atom of atmospheric oxygen is used to O-demethylate the methoxy 
group of AAI to generate AAIa. 
Our present results also demonstrate that the CYP1A-humanized mouse lines used in this 
study are excellent models to further investigate the toxic effects of AAI, as well as the 
effects of other toxic agents (Cheung et al., 2005).  
Curiously, whereas AAI pretreatment of WT mice led to increased CYP1A enzyme 
activities in liver, decreases in these hepatic enzyme activities were observed in both CYP1A-
humanized mouse lines. This is in contrast to the enhanced CYP1A1 expression and also of 
CYP1A2 by TCDD used by Shi et al. (2008) to distinguish the AHR receptors in the two 
lines. There a clear dependence of the induction levels on the AHR receptor affinity was 
observed. The conclusion of these observations is that AAI does not induce human CYP1A 
via the AHR. Since AHR is the only promoter known for CYP1A, AAI is probably not an 
inducer of CYP1A in humans. 
The two CYP1A-humanized mouse lines employed in the study differ in their efficiencies 
to metabolize AAI in different organs. Higher levels of AAI-DNA adducts were formed in 
kidney and liver of both lines, compared with that in WT mice; however, only the high-
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affinity-AHR line showed higher AAI-DNA adduct levels also in lung, bladder, spleen and 
colon. This finding might be explained by the high-affinity AHR being more "sensitive" to 
local concentrations of the inducer AAI in these tissues (than the poor-affinity AHR), thereby 
leading to enhanced reductive metabolism to form the AAI-DNA adducts. Collectively, these 
results indicate that human CYP1A enzymes expressed in these mice favour AAI reduction. 
The overall enhanced DNA adduct formation in high-affinity-AHR mice, compared to low-
affinity-AHR mice, is inversely correlated with the levels of AAIa urinary excretion; higher 
amounts of urinary AAIa were seen in hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd mice than in 
hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1 mice (see Fig. 3). Nevertheless, it should be noted 
that the levels of free AAIa in urine might not reflect the total detoxication of AAI (Arlt et al., 
2011a). Previous studies (Chan et al., 2006; Shibutani et al., 2010) showed that AAIa, which 
is a major metabolite in urine, can form conjugates with glucuronide, sulfate and acetate, 
which could also be excreted in urine and faeces. However, the measurement of these 
conjugates was beyond the scope of the present study.  
The results found in our in-vitro inhibition experiments show that, besides human 
CYP1A1 and 1A2, POR also contributes to AAI-DNA adduct formation, mainly in hepatic 
microsomes of hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1 mice. Thus, the spectrum of enzymes 
involved in AAI reductive bioactivation appear to be different in WT (predominantly 
CYP1A-mediated) and CYP1A-humanized lines (CYP1A- and  POR-mediated), but the  
contribution of CYP1A1 and 1A2 appear not to be very different. These results are consistent 
with our earlier findings that purified POR alone is able to catalyze AAI-DNA adduct 
formation in vitro (Stiborova et al., 2001). However, POR seems to have a rather low, but 
detectable, capacity to activate AAI in hepatic microsomes, compared with CYP1A1 or 1A2 
(Stiborova et al., 2001; present work). The contribution of POR or CYP1A1 and 1A2 to AAI 
reduction is thus dictated by a competition between the active-sites of these enzymes and 
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their quantitative amounts. As demonstrated by the effective inhibition of AAI-DNA adduct 
formation by α-LA in hepatic microsomes from hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1, the 
contribution of POR to AAI activation in hepatic microsomes of this mouse line is higher 
than that in hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd mice. In addition, we found lower 
efficiencies of AAI demethylation to AAIa by human CYP1A1 and 1A2 in in-vitro 
experiments using hepatic microsomes from hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1 than 
from hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd mice. Moreover, these findings were in good 
agreement with the CYP1A1 and 1A2 marker activities (i.e. Sudan I oxidation, EROD and 
MROD). The observations confirm the lower basal CYP1A1 mRNA levels in the low-affinity 
AHR line (Shi et al., 2008). 
AAN patients rapidly progress to end-stage renal disease despite cessation of AA-
containing products (Debelle et al., 2008) and tubulointerstitial hypoxia in chronic kidney 
disease plays a major role in the progression to end-stage renal disease (Mimura and 
Nangaku, 2010). One of the fundamental physiological differences between tumor cells and 
normal cells is the cellular ability to survive under hypoxic conditions, indicating that 
hypoxia is a key regulatory factor in tumor growth (Harris, 2002). Our recent studies in the 
HRN and Cyp1a-knock-out mouse models (Arlt et al., 2011a; Levova et al., 2011) as well as 
our findings of the present study with CYP1A-humanized mice suggest that, in addition to the 
influence of hepatic CYP1A expression, the in vivo oxygen concentrations in tissues may 
affect the balance between AAI nitroreduction and demethylation, thereby influencing the 
level of (geno)toxicity induced. Therefore a low in-vivo oxygen level in the kidney could be a 
critical factor not only in AAI metabolism but also in the potential development of 
tubulointerstitial hypoxia.  
It has been suggested that the hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd line is more 
relevant to human risk assessment vis-à-vis human CYP1A1 and CYP1A2 substrates, 
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because humans have the low-affinity AHR (Shi et al., 2008). Based on this and the present 
data showing a higher potency of the low-affinity-AHR CYP1A-humanized line to detoxify 
AAI, we suggest that a higher proportion of human CYP1A1- and 1A2-catalyzed reactions 
might be attributed to AAI detoxication. In contrast, the role of human CYP1A in AAI 
activation appears to be important only in some organs, predominantly those in which more 
hypoxic conditions occur. Therefore, we evaluated in detail the contribution of human 
CYP1A1 and 1A2 as the key enzymes for AAI demethylating to AAIa in human liver, which 
is the major organ that demethylates AAI. 
Studying hepatic microsomes from fourteen human donors and a panel of human 
recombinant CYPs, we identified the impact of human CYP1A1 and 1A2 in demethylation of 
AAI. High correlation coefficients were found between the activity of CYP1A1 or CYP1A2 
and the AAIa formation. This finding, and the results showing inhibition of only these 
enzymes in human hepatic microsomes, indicate an exclusive role of CYP1A1 and 1A2 in 
AAIa formation in human liver. A major contribution of CYP1A2 (~87%) to this reaction 
was also confirmed by strong inhibition of CYP1A2-mediated AAI demethylation in human 
hepatic microsomes by furafylline. CYP1A1-mediated oxidation of AAI to AAIa is also 
important (~13% contribution), even considering the very low levels of CYP1A1 expression 
in human liver (<1 % of total liver CYP content) (Ikeya et al., 1989; Stiborova et al., 2002; 
2005b). This can be explained by the fact that human recombinant CYP1A1 is the most 
effective CYP enzyme catalyzing AAI demethylation. Although other human recombinant 
CYPs (including CYP2C8, 2C9, 3A4, 1B1, 2D6 and 2E1) were also found to oxidize AAI, 
their contributions to this reaction in human liver appear to be negligible.  
Taking into account previous data showing a major role of human NQO1 in AAI 
activation (Stiborova et al., 2003; 2008; 2011) and results of the present work indicating also 
a role for CYP1A1 and 1A2 in this process, we propose that the pathways of AAI metabolism 
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in humans are mainly dictated by the Km of AAI for human NQO1 versus CYP1A1 and 1A2, 
and their enzymatic turnover, as well as the balance between CYP1A efficiency of AAI 
oxidation versus reduction. Because human CYP3A5 also activates AAI (Levova et al., 2011) 
and is expressed in kidney, the target organ for AA toxicity, its participation in AAI-DNA 
adduct formation in the human urothelium may be of considerable importance. Each of these 
enzymes exhibits polymorphisms (http//cypalleles.ki.se), which are likely to influence further 
each individual’s susceptibility to AA. Indeed, it was reported that human NQO1 genetic 
polymorphisms are important in AA-induced BEN (Toncheva et al., 2004). One of the NQO1 
polymorphisms, the genotype NQO1*2/*2, has already been shown to predispose BEN 
patients to urothelial cancer (OR=13.75, 95% CI 1.17-166.21) (Toncheva et al., 2004). In 
addition, a pilot study has shown a weak association between the human CYP3A5*1 allele 
and BEN (Atanasova et al., 2005).  
Even though CYP1A1 and 1A2 exhibit genetic polymorphisms which subsequently could 
modulate cancer development (Rendic and DiCarlo 1997), there are still no epidemiological 
studies available investigating the involvement of CYP1A1 and 1A2 gene polymorphisms in 
AA-induced kidney injury and cancer development in BEN or AAN patients. Therefore, the 
evaluation of variations in activities and genetic polymorphisms of these human enzymes 
remains a major challenge to explain human inter-individual susceptibility to AA, and to 
predict individual risk of cancer among AAN and BEN patients. 
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Legends for Figures 
FIG. 1. Pathways of AAI biotransformation and AAI-DNA adduct formation. dA-AAI, 7-
(deoxyadenosin-N6-yl)aristolactam I; dG-AAI, 7-(deoxyguanosin-N2-yl)aristolactam I; NR, 
nitroreductase; UGT, UDP glucuronosyl transferase; SULT, sulfotransferase. 
FIG. 2. Quantitative TLC 32P-postlabeling analysis of AAI-DNA adduct formation in organs 
of CYP1A-humanized and WT mice (Arlt et al., 2011a) treated orally with 50 mg/kg body 
weight AAI for 24 hours. F, fold increase in DNA adduct formation in CYP1A-humanized 
mice compared with WT mice. -Ahrb1 = high-affinity-AHR. -Ahrd = poor-affinity AHR. 
Values are given as means ± SD (n = 4); each DNA sample was determined by two 
postlabeled analyses. RAL, relative adduct labeling. Comparison was performed by t-test 
analysis; * P<0.01, different from WT. Insert: Autoradiographic profile of AAI-DNA adducts 
in kidney from WT mice by using the nuclease P1 enrichment version of the assay. The 
adduct profile shown is representative of those obtained in CYP1A-humanized mice and other 
organs (i.e. liver, lung, bladder, spleen and colon). The origin, in the bottom left-hand corner, 
was cut off before exposure. Spot 1, dA-AAI; spot 2, dG-AAI; and spot 3, dA-AAII. 
FIG. 3. Urinary AAIa levels in CYP1A-humanized and WT mice (Arlt et al., 2011a) treated 
orally with 50 mg/kg body weight AAI for 24 h. All values are given as means ± SD (n = 4). 
Comparison was performed by t-test analysis; * P<0.01, different from WT. 
FIG. 4.  DNA adduct formation by AAI in microsomes isolated from CYP1A-humanized and 
WT mice (Arlt et al., 2011a), untreated (A) or pretreated with AAI (B-D). (A) Hepatic 
microsomes from untreated mice were used. Hepatic (B), renal (C), and pulmonary (D) 
microsomes from mice pretreated with AAI were used. Values are given as means ± SD of 
three parallel incubations (n = 3). RAL, relative adduct labelling. Comparison was performed 
by t-test analysis; * P< 0.01, different from WT. 
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FIG. 5. Oxidation of AAI to AAIa by mouse hepatic microsomes isolated from CYP1A-
humanized and WT mice (Arlt et al., 2011a), untreated (A) or pretreated with AAI (E). 
CYP1A enzymatic activity in hepatic microsomes as measured by EROD activity (pmol 
resorufin/min/mg protein) (B, F) MROD activity (C, G) (pmol resorufin/min/mg protein) or 
Sudan I oxidation (pmol total C-hydroxylated metabolites/min/mg protein) (D, H). All values 
are given as means ± SD of three parallel incubations (n = 3). Comparison was performed by 
t-test analysis; * P<0.01, different from WT. 
FIG. 6. Effect of CYP and POR inhibitors on AAI-DNA adduct formation catalyzed by 
hepatic microsomes isolated from CYP1A-humanized and WT mice (Arlt et al., 2011a) 
pretreated with AAI. Values are given as means ± SD of three parallel incubations (n = 3). 
RAL, relative adduct labelling. Comparison was performed by t-test analysis; *P<0.01, 
different from incubation with NADPH alone. Inhibition is compared with percentage DNA 
adduct formation in incubations with NADPH as cofactor only. Control, without cofactor. α-
NF, α-naphthoflavone. E, ellipticine. FF, furafylline. α-LA, α-lipoic acid. ND, not detected. 
FIG. 7. AAIa formation after incubation of AAI with SupersomesTM, each containing a 
different human recombinant CYP (50 nM) (A), and containing these enzymes in 
combination with cytochrome b5 (b5) (B). Values are given as means ± SD of three parallel 
incubations (n = 3). ND, not detected. ##, not determined.  
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Tables 
TABLE 1  
CYP-mediated formation of AAIa form AAI in human hepatic microsomes  
 
CYP-dependent catalytic activitiesa 
 
 
 
 
 
No. 
 
 
pmol 
CYP 
per mg 
protein 
Sudan I 
oxidation in 
presence of 
ketoconazole 
(CYP1A1)b 
 
Phenacetin 
O-deethy-
lation 
(CYP1A2) 
 
 
Coumarin 7-
hydroxylation 
(CYP2A6) 
(S)-
Mephenytoin 
N-demthy-
lation 
(CYP2B6) 
Paclitaxel 
6α-
hydroxy-
lation 
(CYP2C8) 
 
Diclofenac 
4’-
hydroxy-
lation 
(CYP2C9) 
(S)-
Mephenytoin 
4’-hydroxy-
lation 
(CYP2C19) 
 
Burfuralol 
1’-
hydroxy-
lation 
(CYP2D6) 
 
Chloroxazone 
6-hydroxy-
lation 
(CYP2E1) 
 
Testosterone 
6β-hydroxy-
lation 
(CYP3A4) 
Lauric 
acid 12-
hydroxy-
lation 
(CYP4A) 
 
 
 
AAIs 
Peak 
area 
HG93 290 1.1 750 340 25 180 2100 41 56 1800 2400 1600 6.0 
HG03 290 0.9 170 2000 51 200 1700 44 110 1800 6100 1600 2.0 
HG74 220 1.2 520 360 13 130 2100 55 120 1400 2700 1300 7.8 
HG06 300 0.9 770 580 3.0 130 2650 36 ND 1200 2990 740 5.8 
HK27 300 1.6 1320 1320 31 180 480 460 130 3000 4910 1110 10 
HG42 670 0.9 700 2200 150 480 1600 7.0 95 1600 15000 1400 4.0 
HG112 560 0.5 320 490 150 180 4000 380 32 2400 25000 1800 2.7 
HG56 550 3.0 2400 1500 48 180 3100 480 120 1900 5300 3000 18 
HG43 270 1.2 630 850 34 60 1400 700 20 1100 5600 2100 3.8 
HG89 400 1.6 1500 650 60 160 2100 190 13 1700 12000 2200 16 
HG32 170 1.3 730 520 1.0 20 450 5.0 46 1200 2000 680 4.8 
HK31 580 2.5 1220 2160 8.0 130 1690 170 3.0 1660 8210 2010 17.5 
HK23 380 1.6 960 1100 24 160 2100 110 140 2100 6800 780 7.2 
HK34 500 1.6 1000 1500 39 220 1900 45 100 6000 5200 1100 6.15 
Meansc 390 
(150) 
1.4 
(0.6) 
930 
(540) 
1110 
(650) 
46 
(46) 
170 
(100) 
1960 
(890) 
200 
(210) 
76 
(47) 
2060 
(1200) 
7440 
(6010) 
1530 
(630) 
8.0 
(5.2)  
a
 CYP activities in pmol/min/mg protein. CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP4A determined by Gentest. 
b
 pmol total C-hydroxylated metabolites/min/mg protein. 
c Arithmetic means for hepatic microsomal samples of 14 human donors and (SD), representing inter-individual variability.  
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TABLE 2 
Linear regression correlation coefficients among CYP enzyme activities and AAIa formation in human hepatic microsomesa  
 
 
 
 
 
 
 
pmol CYP 
per mg 
protein 
Sudan I 
oxidation in 
presence of 
ketoconazole 
(CYP1A1)b 
 
Phenacetin 
O-deethy-
lation 
(CYP1A2) 
 
 
Coumarin 7-
hydroxylation 
(CYP2A6) 
(S)-
Mephenytoin 
N-demthy-
lation 
(CYP2B6) 
Paclitaxel 
6α-
hydroxy-
lation 
(CYP2C8) 
 
Diclofenac 
4’-hydroxy-
lation 
(CYP2C9) 
(S)-
Mephenytoin 
4’-hydroxy-
lation 
(CYP2C19) 
 
Burfuralol 
1’-hydroxy-
lation 
(CYP2D6) 
 
Chloroxazone 
6-hydroxy-
lation 
(CYP2E1) 
 
Testosterone 
6β-hydroxy-
lation 
(CYP3A4) 
Lauric acid 
12-
hydroxy-
lation 
(CYP4A) 
Correlation 
coefficient 
0.307 0.884 0.932 0.268 -0.265 -0.119 0.067 0.215 -0.123 -0.030 -0.110 0.559 
Significance 0.285 <0.0001 <0.0001 0.355 0.360 0.685 0.820 0.460 0.688 0.919 0.707 0.058 
a
 Data calculated from Table 1. 
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TABLE 3  
Effects of CYP inhibitors on AAI demethylation to AAIa by human hepatic microsomes 
versus human recombinant CYP enzymes 
 
 IC50 (µM) for AAIa formationb 
Inhibitora  Human microsomes Human recombinant CYPs 
α-Napththoflavone (CYP1A1/2) 80.9 ± 6.5 CYP1A1 0.2 ± 0.02 
Furafylline (CYP1A2) 26.8 ± 2.2 CYP1A2 1.5 ± 0.1 
Diamantane (CYP2B6) NIc 
−
d
 − 
Sulfaphenzazole (CYP2C) NI 
− − 
Quinidine (CYP2D6) NI 
− − 
DDTC (CYP2A, CYP2E1) NI 
− − 
Ketoconazole (CYP3A4) 23.5 ± 2.1 CYP3A4 
− 
Ketoconazole  
− 
CYP1A1 0.16 ± 0.02 
Ketoconazole  
− 
CYP1A2 14.3 ± 0.95 
aCYP enzymes that are known to be inhibited by selective inhibitors are shown in brackets. 
bEstimated from concentration-dependent inhibition of AAI metabolite formation by 
interpolation (inhibitors were 1−1000 µM depending on the chemical). AAI (10 µM) and 0.1 
nmol of CYP were present in the incubation mixture. All values represent the mean ± SD of 
three parallel determinations (n = 3). cNI, no inhibition IC50 > 100 µM). dnot determined. 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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